In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosense Webster Inc.

Division of Johnson & Johnson
www.biosensewebster.com

Latest From Biosense Webster Inc.

Starts & Stops: J&J Launches IDE Trial Of 90-Watt RF Ablation Catheter; Vectorious Starts Trial Of V-LAP HF Monitor

Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Feb. 4 through Feb. 10, including from Johnson & Johnson, Relievant Medsystems, Vectorious, Leviticus, and Kaia Health.

Starts & Stops Tracking Trials

Philips Buys Heart Imaging Tech Firm Set Up By Biosense Founder

Philips is bulking-up its image-guided therapy portfolio with the acquisition of EPD Solutions, which has a recently CE-marked cardiac imaging and navigation system for ablation procedures to treat heart arrhythmias. EPD was founded by serial inventor and entrepreneur, Shlomo Ben-Haim, the man behind Johnson & Johnson's Biosense Webster business. 

M & A Cardiology

HRS 2018 Wrap-Up: Tendril Lead Failures; Metaanalysis Of Contact-Force Catheter; LuxCath's OmniView; More Micra Results

The 2018 Heart Rhythm Society scientific sessions in Boston covered a variety of presentations of new electrophysiology clinical data, including a report on the failure of St. Jude's Tendril leads, a meta-analysis of contact-force catheters for atrial-fibrillation ablation, and new data on Medtronic's Micra leadless pacemaker.

Cardiology Clinical Trials

HRS 2018: CABANA Misses Endpoint, Leaving Questions About AF Ablation

The long-awaited results of the CABANA trial, a large randomized study comparing ablation to drug therapy as a first-line treatment for atrial fibrillation, were presented at the Heart Rhythm Society conference in Boston on May 10. The trial missed its primary endpoint in the "intent to treat" analysis, but showed a significant benefit for ablation in the "as-treated" analysis.

Cardiovascular Cardiology
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Biosense Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Johnson & Johnson
  • Senior Management
  • Roy Tanaka, Pres.
  • Contact Info
  • Biosense Webster Inc.
    Phone: (909) 839-8500
    3333 Diamond Canyon Rd.
    Diamond Bar, CA 91765
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register